Doxercalciferol
Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism (overactive parathyroid glands) in adults with chronic kidney disease, as capsules or as an injection given into a vein.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →
Patient information guide — a plain-language walkthrough of Doxercalciferol, written from its FDA label.
What Doxercalciferol is used for
▾
Doxercalciferol treats secondary hyperparathyroidism in adults with chronic kidney disease.
- Doxercalciferol capsules (oral): adults with Stage 3 or Stage 4 CKD.
- Doxercalciferol capsules (oral): adults with CKD on dialysis.
- Doxercalciferol injection (intravenous): adults with CKD on dialysis.
How Doxercalciferol works
▾
Doxercalciferol is a synthetic vitamin D2 analog. The liver activates it, and the active form binds to the vitamin D receptor. This switches on vitamin D pathways and lowers PTH by reducing its production and release.
Activation does not need the kidneys, which matters for people with kidney disease.
Doxercalciferol dosage
▾
Dosing depends on the product and your situation. Always follow your prescriber and the label.
- Capsules: taken by mouth. In Stage 3 or 4 CKD, they are taken once daily. On dialysis, they are taken three times weekly at dialysis.
- Injection: given into a vein as a quick injection at the end of dialysis, three times weekly.
- Your dose is adjusted based on PTH, calcium and phosphorus blood tests.
- If your dose is paused, it is usually restarted a week later at a lower dose.
Dosing details from the FDA-approved label
From the Doxercalciferol prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Patients with CKD on dialysis (Doxercalciferol Injection)
- Initiate at 4 mcg by bolus intravenous administration three times weekly at the end of dialysis (no more frequently than every other day)
- The dose may be increased at 8-week intervals by 1 mcg to 2 mcg if intact PTH is not lowered by 50% and fails to reach the target range
- Maximum: 18 mcg weekly
- Ensure serum calcium is not above the upper limit of normal before starting and is within normal limits before raising the dose. If suspended, restart one week later at a dose at least 1 mcg lower.
- Stage 3 or 4 CKD (Doxercalciferol Capsules)
- Initiate at 1 mcg orally once daily
- The dose may be increased at 2-week intervals by 0.5 mcg to achieve the desired therapeutic range of intact PTH
- Maximum: 3.5 mcg once daily
- Ensure serum calcium is within normal limits before raising the dose. If suspended, restart after one week at a dose at least 0.5 mcg lower.
- CKD on dialysis (Doxercalciferol Capsules)
- Initiate at 10 mcg orally three times weekly at dialysis (no more frequently than every other day)
- The dose may be increased at 8-week intervals by 2.5 mcg to achieve the desired therapeutic range of intact PTH
- Maximum: 20 mcg three times weekly at dialysis for a total of 60 mcg weekly
- Ensure serum calcium is within normal limits before raising the dose. If suspended, restart one week later at a dose at least 2.5 mcg lower.
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Before initiating treatment, ensure serum calcium is not above the upper limit of normal. ( 2.1 ) Dosage for Doxercalciferol Injection in patients with CKD on dialysis:Initiate dosing at 4 mcg by bolus intravenous administration three times weekly at the end of dialysis (no more frequently than every other day). Maximum dose is 18 mcg weekly. ( 2.4 ) Target the maintenance dose of Doxercalciferol Injection to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits. (2) See Full Prescribing Information for dose titration, laboratory monitoring, and important administration instructions. (2 ) 2.1 Prior to Initiation of Doxercalciferol Injection Ensure serum calcium is not above the upper limit of normal before initiating treatment with Doxercalciferol Injection [see Warnings and Precautions (5.1) ]. 2.4 Important Administration Instructions for Doxercalciferol Injection Administer Doxercalciferol Injection intravenously as a bolus dose at the end of dialysis. Inspect Doxercalciferol Injection visually prior to administration; the solution should appear clear and colorless. Do not use if the solution is not clear or particles are present. After initial vial use: - discard unused portion of the single-dose vial; - store opened multiple-dose vial for up to 3 days at 2°C to 8°C (36°F to 46°F). Discard unused portion of multiple-dose vial after 3 days [see How Supplied/Storage and Handling (16) ]. 2.5 Dosage Recommendations for Doxercalciferol Injection in Patients with CKD on Dialysis Initiate Doxercalciferol Injection at a dose of 4 mcg given by bolus intravenous administration three times weekly at the end of dialysis (no more frequently than every other day). Target the maintenance dose of Doxercalciferol Injection to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits. Monitor serum calcium, phosphorus, and intact PTH levels weekly after initiation of therapy or dose adjustment. Titrate the dose of Doxercalciferol Injection based on intact PTH. The dose may be increased at 8-week intervals by 1 mcg to 2 mcg if intact PTH is not lowered by 50% and fails to reach the target range. The maximum dose is 18 mcg weekly. Prior to raising the dose, ensure serum calcium is within normal limits.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Doxercalciferol side effects
▾
Common side effects
- Swelling (edema)
- Headache
- Feeling unwell (malaise)
- Nausea and vomiting
- Dizziness
- Shortness of breath
- Itching
- Slow heart rate
When to get medical help
- Get emergency help for signs of a severe allergic reaction: swelling of the face, lips, tongue or airways, trouble breathing, chest discomfort, or feeling faint or unresponsive.
- Call your doctor if you notice symptoms of high calcium: tiredness, trouble thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination or weight loss.
- Severe high calcium can cause heart rhythm problems and seizures and may need emergency care.
- If you take digitalis medicines, report signs of digitalis toxicity right away.
The most common side effects in people on dialysis include:
- Swelling (edema)
- Feeling unwell (malaise)
- Headache
- Nausea and vomiting
- Dizziness
- Shortness of breath
- Itching
- Slow heart rate
In Stage 3 or 4 CKD, infections, constipation, anemia and cough were also common. Seek help right away for signs of a serious allergic reaction or symptoms of high calcium.
Doxercalciferol warnings and precautions
▾
- High calcium (hypercalcemia): can cause heart rhythm problems and seizures, and severe cases may need emergency care. Long-term high calcium can cause calcium deposits in blood vessels and soft tissues.
- Digitalis toxicity: high calcium raises this risk in people taking digitalis medicines.
- Serious allergic reactions: including fatal cases, reported in people on hemodialysis after the injection.
- Adynamic bone disease: can develop if PTH is pushed too low, raising fracture risk.
Doxercalciferol interactions
▾
Several medicines can change calcium levels or how doxercalciferol works.
- Calcium products, other vitamin D compounds, thiazide diuretics: higher risk of high calcium.
- Digitalis medicines: high calcium can increase toxicity.
- Ketoconazole, erythromycin: may reduce activation of doxercalciferol.
- Glutethimide, phenobarbital: may affect activation, so dose changes may be needed.
- Magnesium-containing antacids: risk of too much magnesium; avoid in chronic dialysis.
- Cholestyramine, mineral oil (capsules): may reduce absorption; space doses apart.
Interactions listed in the FDA-approved label
From the Doxercalciferol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Calcium-containing products, other vitamin D compounds or thiazide diuretics: Concomitant high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia; thiazide diuretics induce hypercalcemia by reducing urinary calcium excretion. Monitor serum calcium concentrations more frequently and adjust doxercalciferol dose as needed.
- Digitalis compounds: Doxercalciferol can cause hypercalcemia, which can potentiate the risk of digitalis toxicity. Monitor for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the doxercalciferol dose.
- Cytochrome P450 inhibitors (e.g., ketoconazole, erythromycin): May inhibit 25-hydroxylation of doxercalciferol and reduce formation of the active doxercalciferol moiety. If a patient initiates or discontinues a cytochrome P450 inhibitor, dose adjustment of doxercalciferol may be necessary. Monitor intact PTH and serum calcium closely.
- Enzyme inducers (e.g., glutethimide, phenobarbital): May affect the 25-hydroxylation of doxercalciferol. If a patient initiates or discontinues an enzyme inducer, dose adjustment of doxercalciferol may be necessary. Monitor intact PTH and serum calcium closely.
- Magnesium-containing products (e.g., antacids): Concomitant high doses of magnesium-containing products may increase the risk of hypermagnesemia. Avoid use of magnesium-containing products and doxercalciferol in patients on chronic renal dialysis.
- Cholestyramine: May reduce intestinal absorption of fat-soluble vitamins and impair absorption of doxercalciferol capsules. Administer doxercalciferol capsules at least 1 hour before or 4 to 6 hours after taking cholestyramine.
- Mineral oil or other substances that may affect absorption of fat: May influence the absorption and availability of doxercalciferol. Administer doxercalciferol capsules at least 1 hour before or 4 to 6 hours after taking mineral oil or other substances that may affect absorption of fat.
Read the label’s full interactions text
7 DRUG INTERACTIONS Tables 3 and 4 include clinically significant drug interactions with doxercalciferol. Table 3: Clinically Significant Drug Interactions with Doxercalciferol Injection and Doxercalciferol Capsules Drugs that May Increase the Risk of Hypercalcemia Clinical Impact Concomitant administration of high doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia. Thiazide diuretics are known to induce hypercalcemia by reducing excretion of calcium in the urine. Examples Calcium-containing products, other vitamin D compounds or thiazide diuretics Intervention Monitor serum calcium concentrations more frequently and adjust doxercalciferol dose as needed [see Warnings and Precautions ( 5.1 )]. Digitalis Compounds Clinical Impact Doxercalciferol can cause hypercalcemia which can potentiate the risk of digitalis toxicity. Intervention Monitor patients for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the dose of doxercalciferol in patients receiving digitalis compounds [see Warnings and Precautions ( 5.2 )]. Cytochrome P450 Inhibitors Clinical Impact Doxercalciferol is activated by CYP 27 in the liver. Cytochrome P450 inhibitors may inhibit the 25-hydroxylation of doxercalciferol and thus reduce the formation of active doxercalciferol moiety [see Clinical Pharmacology ( 12.3 )]. Examples Ketoconazole and erythromycin Intervention If a patient initiates or discontinues therapy with a cytochrome P450 inhibitor, dose adjustment of doxercalciferol may be necessary. Monitor intact PTH and serum calcium concentrations closely. Enzyme Inducers Clinical Impact Doxercalciferol is activated by CYP 27 in the liver. Enzyme inducers may affect the 25-hydroxylation of doxercalciferol [see Clinical Pharmacology ( 12.3 )].
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Doxercalciferol
▾
- Calcium should not be above normal before you start.
- Do not use the injection if you have high calcium, vitamin D toxicity, or a known allergy to it or its ingredients.
- Tell your doctor about liver problems; closer monitoring is needed.
- Pregnancy: data on the injection are limited and not enough to identify a risk.
- Breastfeeding: infants should be watched for signs of high calcium.
- Children: safety and effectiveness of the injection are not established.
- Older adults: dosing is usually started at the low end.
Doxercalciferol overdose
▾
Too much doxercalciferol injection can cause high calcium, high calcium in the urine, and high phosphate. Treatment is supportive care and stopping the drug, with calcium checked until it is normal. Doxercalciferol is not expected to be removed from the blood by dialysis.
What Doxercalciferol does in the body
▾
Doxercalciferol's active form lowers PTH by reducing its production and release. It can also raise calcium and phosphorus levels, which is why they are monitored.
How your body processes Doxercalciferol
▾
The liver (via the enzyme CYP 27) activates doxercalciferol, and the kidneys are not needed. Active levels peak about 8 hours after an IV dose and 11 to 12 hours after capsules. The active form's half-life after an oral dose is about 32 to 37 hours, up to 96 hours. It is not removed from blood by hemodialysis.
How to store Doxercalciferol
▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Store unopened vial in original carton. Store for up to 3 days at 2° to 8°C (36° to 46°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Doxercalciferol
17 supplements and herbal products have documented interactions with Doxercalciferol in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 1
- Moderate · 7
- Minor · 9
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Doxercalciferol: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Doxercalciferol — the kind of thing our pharmacy team would talk through with you at the counter.
What is doxercalciferol for?
▾
How do I take it?
▾
Why do I need so many blood tests?
▾
What side effects should I expect?
▾
Can I take antacids or other supplements with it?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Doxercalciferol available over the counter?
▾
When was Doxercalciferol first available?
▾
Who makes Doxercalciferol?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Doxercalciferol on HelloPharmacist
Doxercalciferol forms and strengths (how it comes)
Doxercalciferol is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Doxercalciferol injection treats secondary hyperparathyroidism in adults with CKD on dialysis.
- Doxercalciferol injection is given into a vein as a bolus (quick injection) at the end of dialysis, three times weekly.
- Doxercalciferol injection should look clear and colorless before use; it is not used if cloudy or containing particles.
- Doxercalciferol injection dosing is adjusted based on PTH and calcium blood tests.
Capsule
How this form is used
- Doxercalciferol capsules treat secondary hyperparathyroidism in adults with Stage 3 or Stage 4 CKD.
- Doxercalciferol capsules also treat secondary hyperparathyroidism in adults with CKD on dialysis.
- Doxercalciferol capsules are taken by mouth; for people on dialysis, they are taken three times weekly at dialysis.
- Doxercalciferol capsules should be taken at least 1 hour before or 4 to 6 hours after cholestyramine or mineral oil.
- Doxercalciferol capsules are dosed based on PTH and calcium blood tests.
Doxercalciferol on the U.S. market: products, makers and brands
How Doxercalciferol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
21 companies list 51 Doxercalciferol product records with the FDA, mostly as injection, capsule; the earliest marketing or approval year on record is 1999. Brand names on the directory include Hectoral, Hectorol; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Doxercalciferol is used (Medicaid data)
A general measure of how commonly Doxercalciferol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Doxercalciferol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Doxercalciferol prescribed? Of the 1,600 medications we measure, Doxercalciferol ranks #818 by Medicaid prescriptions — more than 49% of them.
Utilization by Doxercalciferol product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
doxercalciferol 0.002 MG/ML Injectable Solution
Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 282609
Other Doxercalciferol products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 1 of 18 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Doxercalciferol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 31 listed Doxercalciferol NDCs with Medicaid activity.
Compare Doxercalciferol products
A representative set of FDA-listed product records for Doxercalciferol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 0.5 mcg | — | Catalent Pharma Solutions, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 1 mcg | — | Catalent Pharma Solutions, LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.5 mcg | — | Catalent Pharma Solutions LLC | DRUG FOR FURTHER PROCESSING | View NDC → |
| 0.5 mcg | Oral | Chartwell RX, LLC × 2 listings | ANDA | View NDC → |
| 1 mcg | Oral | Chartwell RX, LLC × 2 listings | ANDA | View NDC → |
| 2.5 mcg | Oral | Chartwell RX, LLC × 2 listings | ANDA | View NDC → |
| 0.5 mcg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 1 mcg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 2.5 mcg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 0.5 mcg | Oral | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 0.5 mcg | Oral | Rising Pharmaceuticals, Inc. | ANDA | View NDC → |
| 1 mcg | Oral | Rising Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mcg | Oral | Rising Pharmaceuticals, Inc. | ANDA | View NDC → |
| 💊Injection | ||||
| 4 mcg/2 mL | Intravenous | Alembic Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Amneal Pharmaceuticals LLC × 4 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | AuroMedics Pharma LLC | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | AuroMedics Pharma LLC × 2 listings | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Dr.Reddy's Laboratories Inc × 2 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Genzyme Corporation × 2 listings | NDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Gland Pharma Limited × 2 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | Hospira, Inc. | NDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Lupin Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 4 mcg/2 mL | Intravenous | Meitheal Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 100 kg/100 kg | — | Assia Chemical Industries Ltd - Teva Tech Site | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Cerbios-Pharma SA | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Formosa Laboratories, Inc. | BULK INGREDIENT | View NDC → |
| 25 kg/25 kg | — | Sai Life Sciences Limited | BULK INGREDIENT | View NDC → |
Showing 51 of 51 products — FDA National Drug Code Directory. See every product, package size and price: browse all 51 Doxercalciferol NDCs →
Doxercalciferol side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Doxercalciferol — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Doxercalciferol in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Doxercalciferol FDA approval history
How Doxercalciferol went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Doxercalciferol recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 11516 3 dose forms · 6 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 378947In current FDA listingsClinical drug / strength (SCD) 0.002 MG/MLRxCUI 282609 -
Dose form (SCDF) Injection RxCUI 1790207In current FDA listingsClinical drug / strength (SCD) 1 ML doxercalciferol 0.002 MG/MLRxCUI 17902082 ML doxercalciferol 0.002 MG/MLRxCUI 1790219 -
Dose form (SCDF) Oral Capsule RxCUI 378939In current FDA listings
Look up RxCUI 11516 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Doxercalciferol supply and shortage status
Whether Doxercalciferol is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Doxercalciferol brand names
Doxercalciferol is sold under 2 brand names in the FDA directory — Hectoral, Hectorol. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Doxercalciferol: manufacturers and labelers
21 companies list Doxercalciferol products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals LLC, Chartwell RX, LLC, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Doxercalciferol drug class (RxNorm)
Doxercalciferol belongs to the Vitamin D2 Analog class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Doxercalciferol page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Meitheal Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →